Leerink Partnrs Issues Pessimistic Outlook for PRCT Earnings

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) – Research analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for PROCEPT BioRobotics in a research report issued on Thursday, August 7th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of ($0.45) for the quarter, down from their prior forecast of ($0.39). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics’ FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.14) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.33) EPS.

A number of other equities analysts also recently issued reports on the company. Stephens initiated coverage on PROCEPT BioRobotics in a research report on Wednesday, July 9th. They set an “overweight” rating and a $70.00 price target on the stock. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a report on Saturday. Bank of America lowered their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, April 25th. Oppenheimer initiated coverage on shares of PROCEPT BioRobotics in a report on Monday, July 7th. They issued a “market perform” rating on the stock. Finally, Piper Sandler lowered their price target on shares of PROCEPT BioRobotics from $80.00 to $55.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of “Moderate Buy” and a consensus price target of $74.88.

PROCEPT BioRobotics Price Performance

PRCT opened at $38.77 on Monday. PROCEPT BioRobotics has a 12-month low of $37.12 and a 12-month high of $103.81. The company has a current ratio of 9.21, a quick ratio of 7.86 and a debt-to-equity ratio of 0.13. The business’s fifty day simple moving average is $56.58 and its 200-day simple moving average is $58.52. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -25.01 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Wednesday, August 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. PROCEPT BioRobotics had a negative return on equity of 23.73% and a negative net margin of 30.60%. The business had revenue of $79.18 million for the quarter, compared to analyst estimates of $75.67 million. During the same quarter last year, the firm posted ($0.50) earnings per share. The business’s revenue was up 48.3% compared to the same quarter last year.

Institutional Investors Weigh In On PROCEPT BioRobotics

Institutional investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd acquired a new stake in shares of PROCEPT BioRobotics during the first quarter worth about $30,000. Thematics Asset Management acquired a new stake in shares of PROCEPT BioRobotics during the fourth quarter worth about $46,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of PROCEPT BioRobotics during the first quarter worth about $40,000. CWM LLC lifted its holdings in shares of PROCEPT BioRobotics by 69.5% during the first quarter. CWM LLC now owns 873 shares of the company’s stock worth $51,000 after purchasing an additional 358 shares during the period. Finally, AlphaQuest LLC lifted its holdings in shares of PROCEPT BioRobotics by 1,262.5% during the second quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after purchasing an additional 1,010 shares during the period. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $61.49, for a total value of $1,537,250.00. Following the completion of the sale, the director owned 14,363 shares of the company’s stock, valued at approximately $883,180.87. This trade represents a 63.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 100,000 shares of company stock valued at $6,271,250 over the last three months. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).